Literature DB >> 19269971

Structure and regulation of the versican promoter: the versican promoter is regulated by AP-1 and TCF transcription factors in invasive human melanoma cells.

Clelia Domenzain-Reyna1, Daniel Hernández, Laia Miquel-Serra, María José Docampo, Celia Badenas, Angels Fabra, Anna Bassols.   

Abstract

Versican is a large chondroitin sulfate proteoglycan of the extracellular matrix that is involved in a variety of cellular processes. We showed previously that versican, which is overexpressed in cutaneous melanomas as well as in premalignant lesions, contributes to melanoma progression, favoring the detachment of cells and the metastatic dissemination. Here, we investigated the transcriptional regulation of the versican promoter in melanoma cell lines with different levels of biological aggressiveness and stages of differentiation. We show that versican promoter up-regulation accounts for the differential expression levels of mRNA and protein detected in the invasive SK-mel-131 human melanoma cells. The activity of the versican promoter increased 5-fold in these cells in comparison with that measured in non-invasive MeWo melanoma cells. Several transcriptional regulatory elements were identified in the proximal promoter, including AP-1, Sp1, AP-2, and two TCF-4 sites. We show that promoter activation is mediated by the ERK/MAPK and JNK signaling pathways acting on the AP-1 site, suggesting that BRAF mutation present in SK-mel-131 cells impinge upon the up-regulation of the versican gene through signaling elicited by the ERK/MAPK pathway. This is the first time the AP-1 transcription factor family has been shown to be related to the regulation of versican expression. Furthermore, deletion of the TCF-4 binding sites caused a 60% decrease in the promoter activity in SK-mel-131 cells. These results showing that AP-1 and TCF-4 binding sites are the main regulatory regions directing versican production provide new insights into versican promoter regulation during melanoma progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269971      PMCID: PMC2673299          DOI: 10.1074/jbc.M807108200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  Cell adhesion and proliferation mediated through the G1 domain of versican.

Authors:  B L Yang; Y Zhang; L Cao; B B Yang
Journal:  J Cell Biochem       Date:  1999-02-01       Impact factor: 4.429

Review 2.  Wnt signalling in stem cells and cancer.

Authors:  Tannishtha Reya; Hans Clevers
Journal:  Nature       Date:  2005-04-14       Impact factor: 49.962

3.  Control of neural crest cell fate by the Wnt signalling pathway.

Authors:  R I Dorsky; R T Moon; D W Raible
Journal:  Nature       Date:  1998-11-26       Impact factor: 49.962

4.  Regulation of the versican promoter by the beta-catenin-T-cell factor complex in vascular smooth muscle cells.

Authors:  Maziar Rahmani; Jason T Read; Jon M Carthy; Paul C McDonald; Brian W Wong; Mitra Esfandiarei; Xiaoning Si; Zongshu Luo; Honglin Luo; Paul S Rennie; Bruce M McManus
Journal:  J Biol Chem       Date:  2005-01-24       Impact factor: 5.157

5.  Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin.

Authors:  Achilleas D Theocharis
Journal:  Biochim Biophys Acta       Date:  2002-11-20

Review 6.  Melanoma genetics and the development of rational therapeutics.

Authors:  Yakov Chudnovsky; Paul A Khavari; Amy E Adams
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

7.  V3 versican isoform expression alters the phenotype of melanoma cells and their tumorigenic potential.

Authors:  Montserrat Serra; Laia Miquel; Clelia Domenzain; María José Docampo; Angels Fabra; Thomas N Wight; Anna Bassols
Journal:  Int J Cancer       Date:  2005-05-10       Impact factor: 7.396

8.  Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin.

Authors:  Qingqing Ding; Weiya Xia; Jaw-Ching Liu; Jer-Yen Yang; Dung-Fang Lee; Jiahong Xia; Geoffrey Bartholomeusz; Yan Li; Yong Pan; Zheng Li; Ralf C Bargou; Jun Qin; Chien-Chen Lai; Fuu-Jen Tsai; Chang-Hai Tsai; Mien-Chie Hung
Journal:  Mol Cell       Date:  2005-07-22       Impact factor: 17.970

9.  Differential expression of versican isoforms in brain tumors.

Authors:  W Paulus; I Baur; M T Dours-Zimmermann; D R Zimmermann
Journal:  J Neuropathol Exp Neurol       Date:  1996-05       Impact factor: 3.685

10.  Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter.

Authors:  M F Naso; D R Zimmermann; R V Iozzo
Journal:  J Biol Chem       Date:  1994-12-30       Impact factor: 5.157

View more
  11 in total

1.  RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration.

Authors:  Neveen Said; Marta Sanchez-Carbayo; Steven C Smith; Dan Theodorescu
Journal:  J Clin Invest       Date:  2012-03-12       Impact factor: 14.808

2.  Repression of versican expression by microRNA-143.

Authors:  Xiaobo Wang; Guoqing Hu; Jiliang Zhou
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

Review 3.  Versican and the regulation of cell phenotype in disease.

Authors:  Thomas N Wight; Michael G Kinsella; Stephen P Evanko; Susan Potter-Perigo; Mervyn J Merrilees
Journal:  Biochim Biophys Acta       Date:  2014-01-05

4.  The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells.

Authors:  Ling Yu; Elvira Favoino; Yangyang Wang; Yang Ma; Xiaojuan Deng; Xinhui Wang
Journal:  Immunol Res       Date:  2011-08       Impact factor: 2.829

5.  A gene expression signature of invasive potential in metastatic melanoma cells.

Authors:  Aaron R Jeffs; Amy C Glover; Lynn J Slobbe; Li Wang; Shujie He; Jody A Hazlett; Anshul Awasthi; Adele G Woolley; Elaine S Marshall; Wayne R Joseph; Cristin G Print; Bruce C Baguley; Michael R Eccles
Journal:  PLoS One       Date:  2009-12-24       Impact factor: 3.240

6.  VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR-PI3K-AKT pathway.

Authors:  Guangyan Zhangyuan; Fei Wang; Haitian Zhang; Runqiu Jiang; Xuewen Tao; Decai Yu; Kangpeng Jin; WeiWei Yu; Yang Liu; Yin Yin; Jintao Shen; Qinfeng Xu; Wenjie Zhang; Beicheng Sun
Journal:  Oncogene       Date:  2019-10-11       Impact factor: 9.867

7.  Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids.

Authors:  Mark Desjardins; Jia Xie; Hilal Gurler; Goda G Muralidhar; Joelle D Sacks; Joanna E Burdette; Maria V Barbolina
Journal:  J Ovarian Res       Date:  2014-06-26       Impact factor: 4.234

8.  Arylsulfatase B regulates versican expression by galectin-3 and AP-1 mediated transcriptional effects.

Authors:  S Bhattacharyya; L Feferman; J K Tobacman
Journal:  Oncogene       Date:  2013-11-18       Impact factor: 9.867

9.  Sharpin promotes hepatocellular carcinoma progression via transactivation of Versican expression.

Authors:  Y Tanaka; K Tateishi; T Nakatsuka; Y Kudo; R Takahashi; K Miyabayashi; K Yamamoto; Y Asaoka; H Ijichi; R Tateishi; J Shibahara; M Fukayama; T Ishizawa; K Hasegawa; N Kokudo; K Koike
Journal:  Oncogenesis       Date:  2016-12-12       Impact factor: 7.485

Review 10.  Proteoglycans Are Attractive Biomarkers and Therapeutic Targets in Hepatocellular Carcinoma.

Authors:  Yasuo Tanaka; Ryosuke Tateishi; Kazuhiko Koike
Journal:  Int J Mol Sci       Date:  2018-10-08       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.